2021
Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
Low J, Huang Y, Sooi K, Ang Y, Chan Z, Spencer K, Jeyasekharan A, Sundar R, Goh B, Soo R, Yong W. Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer. International Journal Of Cancer 2021, 149: 169-176. PMID: 33634869, PMCID: PMC9545741, DOI: 10.1002/ijc.33534.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerProgression-free survivalCell lung cancerFood and Drug AdministrationOverall survivalTreatment of advanced non-small cell lung cancerLung cancerDose of pembrolizumabImmune-related toxicitiesEffectiveness of pembrolizumabWeight-based dosingRetrospective observational studyNational University HospitalDegrees of cost savingsCost-minimisation analysisFixed doseSurvival outcomesAsian patientsNo significant differencePembrolizumabOncogenic driversSingle agentLow dosesRandomised trials
2020
Concomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia.
Sundar R, Magarajah G, Ow S, Chan G, Choo J, Eng L, Wong A, Vijayan J, Hairom Z, Ang E, Paxman R, Wilder-Smith E, Thakor N, Lee S, Bandla A. Concomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia. Journal Of Clinical Oncology 2020, 38: e24157-e24157. DOI: 10.1200/jco.2020.38.15_suppl.e24157.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPaclitaxel-induced neuropathyChemotherapy-induced alopeciaPost-chemotherapyScalp coolingAdverse effects of paclitaxelPreservation of nerve functionWeekly paclitaxel chemotherapyToxicity of paclitaxelEffects of paclitaxelReducing chemotherapy-induced alopeciaBreast cancer patientsLimb hypothermiaProof-of-concept studyPaclitaxel chemotherapyHypothermia trialTransient erythemaNo significant differencePatient toleranceRandomized studyNerve functionPre-chemotherapyPeripheral neuropathyChemotherapyCancer patients